Literature DB >> 29026210

Bispecific antibody pipeline moves beyond oncology.

Asher Mullard.   

Abstract

This corrects the article DOI: 10.1038/nrd.2017.187.

Year:  2017        PMID： 29026210     DOI： 10.1038/nrd.2017.211

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  1 in total

1.  Bispecific antibody pipeline moves beyond oncology.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2017-09-29       Impact factor: 84.694
  1 in total
  3 in total

Review 1.  Aligning physics and physiology: Engineering antibodies for radionuclide delivery.

Authors:  Wen-Ting K Tsai; Anna M Wu
Journal:  J Labelled Comp Radiopharm       Date:  2018-05-15       Impact factor: 1.921

2.  Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment.

Authors:  Hung-Jun Lin; Tien-Li Liang; Yao-Yuan Chang; Der-Zen Liu; Jia-Yu Fan; Steve R Roffler; Shyr-Yi Lin
Journal:  Pharmaceutics       Date:  2022-06-05       Impact factor: 6.525

3.  Variable heavy-variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assembly.

Authors:  Joerg Thomas Regula; Sabine Imhof-Jung; Michael Mølhøj; Joerg Benz; Andreas Ehler; Alexander Bujotzek; Wolfgang Schaefer; Christian Klein
Journal:  Protein Eng Des Sel       Date:  2018-07-01       Impact factor: 1.650
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.